ERCC1 and urothelial carcinoma: In a retrospective study of 57 patients with documented metastatic or locally advanced, surgical incurable (T4b, N0-1) urothelial carcinoma (including bladder and upper tract), patients with low levels of ERCC1 mRNA expression had significantly longer median OS (25.4 months versus 15.4 months, p = 0.03) and increased time to disease progression than those with higher ERCC1 expression [65].